ADHD - Combined Type study: Methylphenidate
Official title Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
ClinicalTrials.gov ID: NCT04781972
What this study is testing
What is Methylphenidate?
An investigational single‑dose medication being studied for ADHD – combined type. is designed to increase dopamine and norepinephrine levels in the brain.
Also referred to as Ritalin.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if brain scans can predict who will respond to methylphenidate by measuring changes in brain activity and glutamate levels after treatment.
- Who it's for
- Adults who have been diagnosed with combined type ADHD.
- What's involved
- Participants will receive a single dose of either methylphenidate or a placebo, then undergo brain scans (fMRI and MRS) and neuropsychological tests.
- Time commitment
- The study lasts a few days, with each participant having two visits, one for each treatment, plus the scans and tests at each visit.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 40
You may be able to join if
- right handed
You likely can't join if
- pregnant or breast feeding
- past or current neurological disorder
- non-ADHD cause of cognitive impairment
- uncontrolled medical disorder
- head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
- having an adverse reaction to methylphenidate, or other stimulant medication
See the full eligibility criteria
- right handed
- pregnant or breast feeding
- past or current neurological disorder
- non-ADHD cause of cognitive impairment
- uncontrolled medical disorder
- head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma
- having an adverse reaction to methylphenidate, or other stimulant medication
- having a contraindication to MRI
- current smoking
The study team makes the final eligibility decision.
Where it is enrolling
- Baltimore, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 40 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Baltimore, Maryland, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.